BRISTOL MYERS SQUIBB
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 69
- Registration Number
- NCT00326716
- Locations
- ๐บ๐ธ
Triple O Medical Services, P.A., West Palm Beach, Florida, United States
๐บ๐ธWomen's Hospital Of Texas, Houston, Texas, United States
๐ฟ๐ฆLocal Institution, Westdene, Gauteng, South Africa
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
- Conditions
- Cancer
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00326131
- Locations
- ๐บ๐ธ
Local Institution, San Antonio, Texas, United States
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 681
- Registration Number
- NCT00324155
- Locations
- ๐บ๐ธ
Thompson Cancer Survival Center, Knoxville, Tennessee, United States
๐บ๐ธProvidence Portland Medical Center, Portland, Oregon, United States
๐บ๐ธSt Joseph Oncology Inc, Saint Joseph, Missouri, United States
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 75
- Registration Number
- NCT00323882
- Locations
- ๐บ๐ธ
Washington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
๐บ๐ธThe Angeles Clinic and Research Institute, Los Angeles, California, United States
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Myeloid Leukemia, Chronic, Chronic-Phase
- First Posted Date
- 2006-05-10
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00324077
- Locations
- ๐บ๐ธ
Local Institution, New York, New York, United States
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00320190
- Locations
- ๐ฌ๐ง
Local Institution, Leeds, North Yorkshire, United Kingdom
A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer
- Conditions
- Pulmonary EmbolismCancerThrombosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00320255
- Locations
- ๐บ๐ธ
Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธUniv. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธMount Sinai School Of Medicine, New York, New York, United States
Safety Study of Apixaban in Recent Acute Coronary Syndrome
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1741
- Registration Number
- NCT00313300
- Locations
- ๐บ๐ธ
Midwest Cardiology Research Foundation, Columbus, Ohio, United States
๐บ๐ธGeorgia Heart Specialists, Covington, Georgia, United States
๐บ๐ธHeartcare Midwest, Peoria, Illinois, United States
A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome
- Conditions
- HIV Infections
- First Posted Date
- 2006-04-11
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT00312754
- Locations
- ๐ซ๐ท
Local Institution, Paris, France
Study of BMS-663513 in Patients With Advanced Cancer
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT00309023
- Locations
- ๐บ๐ธ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
๐บ๐ธCity Of Hope National Medical Center, Duarte, California, United States
๐บ๐ธYale University School Of Medicine, New Haven, Connecticut, United States